The Chemical Basis of Pharmacology
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Molecular biology now dominates pharmacology so thoroughly that it is difficult to recall that only a generation ago the field was very different. To understand drug action today, we characterize the targets through which they act and new drug leads are discovered on the basis of target structure and function. Until the mid-1980s the information often flowed in reverse: investigators began with organic molecules and sought targets, relating receptors not by sequence or structure but by their ligands. Recently, investigators have returned to this chemical view of biology, bringing to it systematic and quantitative methods of relating targets by their ligands. This has allowed the discovery of new targets for established drugs, suggested the bases for their side effects, and predicted the molecular targets underlying phenotypic screens. The bases for these new methods, some of their successes and liabilities, and new opportunities for their use are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Self-citationPredicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667 · cited 4×
“While these two activities were found for weakly binding off targets, this is not always the case; the antihypertensive Doralese unexpectedly bound the dopamine D4 receptor a log order more tightly (18 nM) than it does its canonical R-adrenergic on target (200-600 nM) (41).”
BackgroundMethodInfluentialSelf-citationDrug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248 · cited 2×
“screens (58), and predicted off-targets and new disease indications for drugs (40).”
BackgroundThe Connectivity Map: A new tool for biomedical research
Lamb, J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2044 · Cited by 945 · cited 1×
“Using theirMode of Action by Network Analysis (MANTRA) method, the authors leveraged the ConnectivityMap (49, 50) collection to group drugs into “communities” by similarities in their patterns of specific transcriptional responses.”
MethodDiscovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535
Integrating high-content screening and ligand-target prediction to identify mechanism of action
Young, D. W., Bender, A., Hoyt, J., McWhinnie, E., Chirn, G.-W., Tao, C. Y., Tallarico, J. A., Labow, M., Jenkins, J. L., Mitchison, T. J., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.2007.53 · Cited by 345
Agonist Properties of N,N-Dimethyltryptamine at Serotonin 5-HT2A and 5-HT2C Receptors
Smith, R. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00110-5 · Cited by 147 · cited 1×
“This was surprising given the promiscuous and sometimes potent activity on σ1 of many non-hallucinogens, and DMT binds targets already implicated in hallucination, the serotonin receptors (54-56).”
Background
Cited by
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
A practical guide to large-scale docking
Bender, B. J., Gahbauer, S., Luttens, A., Lyu, J., Webb, C. M., Stein, R. M., Fink, E. A., Balius, T. E., Carlsson, J., Irwin, J. J., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00597-z · Cited by 546
“While the libraries physically screened in HTS were an enormous expansion on those used by classical, pre-molecular pharmacology 3 , they nevertheless represent only a tiny fraction of possible ‘ drug-like ’ molecules 4 .”
MethodSelf-citationVatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Super Natural II—a database of natural products
Banerjee, P., Erehman, J., Gohlke, B.-O., Wilhelm, T., Preissner, R., & Dunkel, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku886 · Cited by 318
Structure-based drug screening for G-protein-coupled receptors
Shoichet, B. K., & Kobilka, B. K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.007 · Cited by 294
Self-citation
Metadata
- Authors
- Keiser, M. J., Irwin, J. J., & Shoichet, B. K.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-11-12
- Volume
- 49
- Issue
- 48
- Pages
- 10267-10276
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2001415793
- Cited by
- 94
- References
- 9
- FWCI
- 18.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.